FCGR3A and COVID-19: The spike-specific and the RBD-specific antibodies of COVID-19 patients with more severe disease have been found to have lower fucosylation of their Fc domains (118), which is associated with increased binding to the activatory Fc receptor FcγRIIIa, hypothesised to cause immunopathology.